The protein drug developer has now secured more than $195m in total, its earlier backers including GlaxoSmithKline, Pfizer, Eli Lilly and Schrödinger.

Cancer drug developer ImmuneOnco has caught the attention of Eli Lilly's Asia-focused vehicle and will put the series B proceeds toward clinical trials.

Alphabet subsidiary GV led a $16.5m series A round for the healthcare revenue management startup that followed a $6m round last year.

Novartis Venture Fund and Novo Seeds co-led a $10.4m round for oncology therapy developer Rappta on behalf of corporate parents Novartis and Novo.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

Eli Lilly participated in a $57.6m round that will support the identification and preclinical development of Cedilla's first two small molecule product candidates.

Roivant Sciences, Cigna Ventures and Johnson & Johnson Innovation – JJDC helped push the healthcare data exchange's overall funding to $83m.

Sony Innovation Fund by IGV and Salesforce Ventures have contributed to a $17.1m round for the medical technology developer, bringing its overall funding to roughly $50m.

Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.